Incyte
DE - Wilmington
Biotechnology10 H-1B visas (FY2023)Focus: Small Molecules
Incyte is a life sciences company focused on Small Molecules.
OncologyImmunology
Open Jobs
0
Products & Portfolio (5)
JAKAFI
ruxolitinib
LOE Approaching
ORAL · TABLET
Janus Kinase Inhibitors
2011
15
NIKTIMVO
axatilimab-csfr
Growth
mAbINTRAVENOUS · INJECTABLE
Colony Stimulating Factor Receptor Type 1 (CSF-1R) Inhibitors
2024
30
OPZELURA
ruxolitinib
Peak
TOPICAL · CREAM
Ruxolitinib, a Janus kinase (JAK) inhibitor, inhibits JAK1 and JAK2 which mediate the signaling of a number of cytokines and growth factors that are important for hematopoiesis and immune function. JAK signaling involves recruitment of STATs (signal transducers and activators of transcription) to cytokine receptors, activation and subsequent localization of STATs to the nucleus leading to modulation of gene expression. The relevance of inhibition of specific JAK enzymes to therapeutic effectiveness is not currently known.
atopic dermatitis
2021
0
PEMAZYRE
pemigatinib
Peak
ORAL · TABLET
Kinase Inhibitors
2020
0
ZYNYZ
retifanlimab-dlwr
Peak
mAbINTRAVENOUS · INJECTABLE
Programmed Death Receptor-1-directed Antibody Interactions
2023
30
Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Founded: 2012
Portfolio: 5 approved products, 100 clinical trials
Top TAs: Oncology, Immunology, Dermatology
H-1B (2023): 10 approvals
Portfolio Health
Growth1 (20%)
Peak3 (60%)
LOE Approaching1 (20%)
5 total products
Therapeutic Area Focus
Oncology
4 marketed255 pipeline
Immunology
1 marketed47 pipeline
Dermatology
32 pipeline
Hematology
30 pipeline
Infectious Diseases
7 pipeline
Nephrology
4 pipeline
Metabolic Diseases
4 pipeline
Gastroenterology
3 pipeline
Marketed
Pipeline
Visa Sponsorship
Sponsors Work Visas
H-1B Petitions (FY2023)
10
Approved
0
Denied
100%
Rate
Source: USCIS H-1B Employer Data Hub